- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03919773
IVIG (Gamunex-C) Treatment Study for POTS Subjects (iSTAND)
IVIG (Gamunex-C) Study of Treatment for Autoimmune Neuropathic Dysautonomia/Postural Tachycardia (POTS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Gammunex-C, a form of intravenous immunoglobulin (IVIG), is approved for the treatment of chronic inflammatory demyelinating neuropathy (CIDP) or idiopathic thrombocytopenic purpura (ITP). IVIG has been in use for many decades in the treatment of these disorders and many other inflammatory/autoimmune diseases. It is generally very safe and well tolerated. More recently, IVIG has been proposed as an effective treatment for presumed inflammatory neurological disorders which do not meet the criteria for CIDP. Specifically, case reports and cases series have indicated therapeutic responses to IVIG in autonomic neuropathies.
Intravenous Albumin is approved for the treatment of hypovolemia (see attached package insert). The use of albumin to increase plasma volume in patients with POTS has been suggested. In this study, albumin will be used as an active control treatment to provide the same volume and protein load as IVIG but without the immunomodulatory effects.
There have been few well designed clinical therapy trials aimed at POTS patients and even fewer that are aimed at a particular pathophysiological subtype of POTS. Evidence suggests that POTS is a heterogeneous disorder with differing underlying mechanisms. Several uncontrolled case series have suggested a benefit of IVIG for POTS, but the volume expansion associated with infusion of IVIG make it difficult to assess the immunomodulatory effects of this treatment. We propose to evaluate the efficacy of IVIG using a double-blind randomized cross over design that will determine efficacy while reducing effects of inter-subject variability and placebo effect which are common problems in POTS therapy research. Even with the statistical advantages of a crossover design, the treatment cohort will be small, and this study is designed to be a pilot (phase II) study to evaluate the feasibility, tolerability and potential benefits of treatment. The results of this pilot study will provide the impetus and rationale for a larger multicenter clinical trial to definitively evaluate immunomodulatory treatment in POTS.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75208
- UT Southwestern Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 years of age or older, and able to provide informed consent
- Diagnosis of POTS (see Table 1)
- COMPASS-31 symptom score showing moderate to severe autonomic symptoms
At least 3 of the following clinical or laboratory features of autoimmunity
- One or more serum autoantibodies (ANA ≥ 1:160, gAChR antibody > 0.2 nmol/L, positive ENA, aPL, TTG, gliadin) or inflammatory markers (ESR > 30, CRP > 2, low C3 complement or low immunoglobulin IgG level)
- Confirmed personal history or family history of defined autoimmune disease including Hashimoto's thyroiditis, celiac disease, antiphospholipid syndrome, rheumatoid arthritis, SLE, or Sjogren's syndrome
- Clear history of acute or subacute onset following infection, immunization, injury/concussion, surgery or pregnancy.
- Evidence of esophageal, gastric or intestinal dysmotility (with weight loss)
- Evidence of small fiber neuropathy (abnormal QSART or IENFD)
- Stable oral medical therapy for past 3 months
- Ambulatory at time of screening
Exclusion Criteria:
- Current or previous immunosuppression therapy or IVIG treatment
- Contraindication to intravenous immunoglobulin or intravenous albumin
- Known allergic reactions to blood products including intravenous immunoglobulin (IVIG) and/or subcutaneous immunoglobulin (SCIG), such as history of clinically relevant hemolysis after IVIG infusion, aseptic meningitis, recurrent severe headache, hypersensitivity, severe generalized or severe local skin reaction.
- Inadequate peripheral venous access
- Evidence of renal insufficiency (Cr > 1.5 x elevated) or liver disease (transaminases > 2.5x upper limit) at screening
- History of thrombotic episode within 3 years of enrollment
- Other major medical issue which, in investigators opinion, increases risk for adverse event over the next 12 months or may require separate management.
- Female patients who are premenopausal and are (a) pregnant based on serum pregnancy test, or (b) breast-feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment IVIG Arm
IVIG (Gammunex-C) infusion (0.4 gm/kg) every week for 4 weeks, then every 2 weeks for 8 weeks (12 weeks total).
|
If you participate in this study there will be 18 scheduled treatment infusions during the 30 week study period. All the study visits and treatment visits will be outpatient visits. Once you qualify to participate in the study and begin treatment, there will be two 12 week treatment periods separated by a 6 week washout period. The infusion visits will take approximately 3-4 hours each.
Other Names:
|
Placebo Comparator: Treatment Albumin Arm
albumin infusion (0.4 gm/kg) every week for 4 weeks then every 2 weeks for 8 weeks (12 weeks total) during
|
This will be the matching placebo used in the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in symptoms measured by change in COMPASS-31 score.
Time Frame: 12 weeks
|
Primary outcome with POTS symptoms
|
12 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Steven Vernino, MD, PhD, UT Southwestern Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Nervous System Diseases
- Arrhythmias, Cardiac
- Cardiac Conduction System Disease
- Autonomic Nervous System Diseases
- Primary Dysautonomias
- Orthostatic Intolerance
- Tachycardia
- Postural Orthostatic Tachycardia Syndrome
- Physiological Effects of Drugs
- Immunologic Factors
- Immunoglobulins
- Immunoglobulins, Intravenous
- gamma-Globulins
- Rho(D) Immune Globulin
Other Study ID Numbers
- STU-2018-0005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postural Tachycardia Syndrome
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingPostural Tachycardia Syndrome (POTS)United States
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedPostural Tachycardia Syndrome (POTS)United States
-
Mayo ClinicNot yet recruitingPostural Tachycardia Syndrome | Postural Orthostatic Tachycardia Syndrome | Autonomic Dysfunction | POTS - Postural Orthostatic Tachycardia SyndromeUnited States
-
argenxIqvia Pty LtdRecruitingPost-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia SyndromeUnited States
-
AtriCure, Inc.RecruitingPostural Tachycardia Syndrome | Inappropriate Sinus TachycardiaBelgium
-
University of CalgaryDysautonomia InternationalRecruiting
-
University of CalgaryCompleted
-
University of CalgaryRecruiting
-
Mayo ClinicNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingPostural Tachycardia SyndromeUnited States
-
Insel Gruppe AG, University Hospital BernActive, not recruiting
Clinical Trials on IVIG
-
Tabriz University of Medical SciencesCompletedRecurrent Implantation FailureIran, Islamic Republic of
-
Vanderbilt University Medical CenterCSL BehringRecruiting
-
Tabriz University of Medical SciencesCompletedRecurrent Pregnancy LossIran, Islamic Republic of
-
Novartis PharmaceuticalsCompleted
-
Azidus BrasilSichuan Yuanda Shuyang Pharmaceutical Co., Ltd.Not yet recruitingPrimary Immunodeficiency Disease
-
Azidus BrasilBoya Bio Pharmaceutical Group Co LtdNot yet recruitingPrimary Immunodeficiency Disease
-
Shanghai Changzheng HospitalNot yet recruitingBacteremia | Viremia | Acute Rejection of Renal Transplant
-
Assistance Publique - Hôpitaux de ParisUnknownAutoimmune Diseases | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Clarkson Syndrome | Muscular Autoimmune DisordersFrance
-
Hormozgan University of Medical SciencesCompletedNeonatal SepsisIran, Islamic Republic of
-
University of South FloridaBaxter Healthcare CorporationCompletedSpinocerebellar AtaxiaUnited States